BSE Live
Apr 08, 16:01Prev. Close
1202.25
Open Price
1239.90
Bid Price (Qty.)
1215.80 (9)
Offer Price (Qty.)
1220.00 (70)
NSE Live
Apr 08, 15:59Prev. Close
1202.40
Open Price
1220.00
Bid Price (Qty.)
1215.90 (195)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Cipla (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 2,964.31 | 2,492.83 | 1,911.40 | 1,186.94 | 1,743.97 | |
| Net CashFlow From Operating Activities | 2,018.14 | 1,468.05 | 1,116.53 | 2,207.39 | 1,728.40 | |
| Net Cash Used In Investing Activities | -1,126.33 | -1,147.05 | -592.16 | -1,191.25 | -1,205.67 | |
| Net Cash Used From Financing Activities | -693.89 | -473.32 | -350.96 | -1,010.80 | -547.00 | |
| Foreign Exchange Gains / Losses | -0.85 | -0.66 | -0.56 | -0.50 | -0.31 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 197.07 | -152.98 | 172.85 | 4.84 | -24.58 | |
| Cash And Cash Equivalents Begin of Year | 64.47 | 217.45 | 44.60 | 39.76 | 64.34 | |
| Cash And Cash Equivalents End Of Year | 261.54 | 64.47 | 217.45 | 44.60 | 39.76 |
01.04.2026
19.03.2026
04.03.2026
Cipla to form JV with Kemwell Biopharma; share price down marginally
04.03.2026
27.01.2026
Cipla Consolidated December 2025 Net Sales at Rs 7,074.48 crore, up 0.02% Y-o-Y
27.01.2026
Cipla Standalone December 2025 Net Sales at Rs 4,498.08 crore, down 9.51% Y-o-Y
10.11.2025
Cipla Standalone September 2025 Net Sales at Rs 5,225.72 crore, up 9.44% Y-o-Y
03.11.2025
Cipla Consolidated September 2025 Net Sales at Rs 7,589.44 crore, up 7.64% Y-o-Y
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
09.05.2024
17.04.2024
Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities
12.07.2023
28.01.2025
30.10.2024
Multiple near-term challenges may hijack Cipla's growth trajectory
13.05.2024
06.11.2018
Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth